Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?
暂无分享,去创建一个
[1] F. Pitoia,et al. Erratum to: Biochemical persistence in thyroid cancer: is there anything to worry about? , 2014, Endocrine.
[2] A. Erika,et al. Biochemical persistence in thyroid cancer: is there anything to worry about? , 2014, Endocrine.
[3] R. Tuttle,et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.
[4] R. Tuttle,et al. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.
[5] G. Cevenini,et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.
[6] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[7] R. Tuttle,et al. Contemporary post surgical management of differentiated thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[8] Stephanie L. Lee,et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.